OWL-LABS
23.6.2021 01:03:07 CEST | Business Wire | Press release
Research conducted by Owl Labs , which polled 2000 business leaders* based in the UK, Germany, France, and the Nordics** shows that just 11% of business leaders expect their employees to return to the office full-time, indicating a more permanent shift to hybrid working. What’s more, the majority of European organisations (92%) are keen to explore progressive policies post-pandemic including introducing working from anywhere (42%), core working hours (39%), a four-day week (39%), and unlimited holiday (22%). When considering why employers are permanently moving to a more flexible work model, profitability plays an important role. Close to two-thirds (62%) of European business leaders reported that hybrid working makes companies more profitable with Enterprise businesses (1000+ employees) the most likely to think so (73%) versus small and medium-sized companies (55%).
As businesses continue to adapt to working in a Covid-19 environment, over a third (39%) of European business leaders anticipate that Covid-19 will continue to impact the running of their business for up to six months. French business leaders are the most optimistic with one in five (20%) believing Covid-19 would only impact the running of their office for the next three months or less. However, the majority believe that remote and hybrid working has positively impacted their business, with the majority stating it had impacted employee wellbeing (52%) and business costs (50%) positively.
With a growing desire to support employees' partial return-to-office, one in four EU organisations (24%) are now planning to enforce ‘vaccine passports’ and only allow those who have been vaccinated into the office. Germany is the most cautious with 31% of business leaders insisting on Covid-19 vaccines, while 23% of business leaders in the UK, 21% in the Nordics and 19% in France intend to enforce vaccines. Additionally, over a third (38%) of EU business leaders are considering providing onsite Covid-19 testing facilities to encourage employees to return to work, with French and German organisations most likely to provide onsite testing facilities at 42% and 43% respectively.
European organisations are already planning ahead to a post-pandemic work environment, with the majority of business leaders (63%) aiming to maintain the same amount of office space, even with the rise of hybrid work. Just 11% are planning to get rid of their offices entirely (rising to 14% in the Nordics). When it comes to hiring, one-third of EU organisations (32%) plan to hire employees who can work remotely, based on skill, rather than their proximity to an office. In a move that may not be welcomed by employees, 29% of business leaders plan to use productivity apps to monitor activity of remote employees. This rises steeply in Germany, where 37% of business leaders plan on utilising productivity and activity monitoring of remote employees, compared to just 22% of Nordic business leaders.
As businesses move to hybrid and flexible working, technology plays a crucial role in enabling this shift. As a result, the majority (93%) of European organisations are putting workplace policies and infrastructure in place to prepare for a post-pandemic workplace. This includes nearly half (42%) of European businesses investing in new tech and solutions to support a hybrid workforce. The UK leads the tech charge with 43% investing in communications tools (such as Slack, Zoom, and Meeting Owl conference cameras) compared to 28% in the Nordics, 36% in France and 38% in Germany. The primary activities companies are carrying out to prepare their workplaces now and post-pandemic are:
○ Investing in communication tools and technology (Slack, Zoom, conference cameras, Meeting Owls, etc.) (36%)
○ Continued social-distancing measures for employees in the office (35%)
○ Providing at-home and in-office equipment for employees so they can easily work from both locations (33%)
Frank Weishaupt, CEO of Owl Labs says, “It’s encouraging to see business leaders across Europe embrace hybrid work post-pandemic. As organisations have adapted to working remotely, they’ve seen the benefits. The ability to hire remote teams from anywhere, leverage new technologies whilst saving on costs. We know that technology will continue to play a key role in supporting this permanent shift to hybrid work, and businesses that will be successful will create the infrastructure and workplace policies that enable their employees to maintain high levels of creativity and collaboration, wherever they dial-in from.”
---ends---
Methodology:
* Business Leaders refer to C-suite executives, heads of departments, HR managers and general managers
**The Nordics refers to Sweden, Finland, Norway & Denmark
About Owl Labs
Owl Labs is a collaborative technology company dedicated to creating a better workplace and learning experience for today's hybrid workforce and virtual classroom. The company’s flagship product, the award-winning Meeting Owl Pro , features a wifi-enabled, portable 360° camera, mic, and speaker with proprietary AI technology that automatically focuses on who is speaking using audio and visual cues. The company is a recipient of TIME’s Best Inventions of 2020 and is dedicated to providing collaborative and productivity solutions for organizations to stay connected to their remote employees and educators to stay connected to their remote students, regardless of location. Learn more at www.owllabs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005955/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
